OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. Its flagship program is OKI-219, a selective PI3KαH1047R inhibitor. The Company operates in one operating segment: clinical research.